ACT Laboratories Acquires CDX Analytics
September 28, 2022
ACT Laboratories, Inc. has agreed to acquire CDX Analytics, LLC to expand its cannabis and hemp testing footprint into Massachusetts. ACT Labs — majority owned by Intrinsic Capital Partners — said the deal (subject to Massachusetts regulatory approval) will extend its multistate laboratory network and enhance capacity and scientific capabilities for local cultivators, processors and dispensaries.
- Buyers
- ACT Laboratories, Inc., Intrinsic Capital Partners
- Targets
- CDX Analytics, LLC
- Platforms
- ACT Laboratories, Inc.
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
ACT Genomics Acquires MC Diagnostics
August 10, 2021
Medical Devices
Taiwan-based precision medicine company ACT Genomics has acquired North Wales–headquartered molecular diagnostics specialist MC Diagnostics (MCD). The deal gives ACT Genomics access to MCD’s ALDAS microarray platform and point-of-care testing capabilities, supporting ACT’s expansion into Europe and development of additional genechip-based diagnostic products.
-
SC Labs Acquires C4 Laboratories
April 24, 2023
Healthcare Services
SC Labs, a leading U.S. cannabis and hemp testing company headquartered in Santa Cruz, California, has acquired C4 Laboratories of Scottsdale, Arizona. The acquisition expands SC Labs' licensed and accredited footprint to five states and adds C4's advanced cannabis testing capabilities to SC Labs' national testing and compliance platform.
-
BioAgilytix Acquires Cambridge Biomedical
November 4, 2019
Healthcare Services
BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.
-
Agno Pharma Acquires Actylis Eugene (Legacy Cascade Chemistry) in Eugene, Oregon
January 15, 2026
Pharmaceuticals
Agno Pharma has acquired Actylis Eugene, the legacy Cascade Chemistry manufacturing asset in Eugene, Oregon, expanding Agno's U.S. cGMP API development and manufacturing footprint. The site includes a 16,000 sq. ft. R&D lab and a newly constructed 30,000 sq. ft. GMP manufacturing facility, enhancing Agno's capabilities to support biotech and pharmaceutical clients from early-phase through commercial API production.
-
Cresco Labs Acquires Cultivate in Massachusetts
September 3, 2021
Retail
Cresco Labs has closed its acquisition of Cultivate, a vertically integrated Massachusetts cannabis operator with three dispensaries and approximately 42,000 square feet of active cultivation canopy. The deal increases Cresco's in-state cultivation to ~64,000 square feet and expands its retail footprint in Massachusetts as part of a strategy to deepen presence in large, attractive state markets.
-
The Cannabist Company Acquires Ciencia Labs Portfolio
December 11, 2024
Retail
The Cannabist Company (formerly Columbia Care) acquired the Ciencia Labs portfolio earlier in 2024 and is launching the Ciencia Labs brand dreamt in Maryland, with additional markets and products planned for 2025. The acquisition expands The Cannabist Company’s branded product offerings and supports broader retail and wholesale distribution across its dispensary and wholesale channels.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.